HZNP - Horizon Therapeutics shareholders overwhelmingly approve acquisition by Amgen
- More than 99% Horizon Therapeutics ( NASDAQ: HZNP ) shareholders who voted during a special meeting did so in favor of the company's acquisition by Amgen ( NASDAQ: AMGN ).
- That figure represented about 76% of total Horizon ( HZNP ) shares.
- The $28B acquisition is facing FTC scrutiny as the agency issued a "second request" to Amgen ( AMGN ) at the end of January for additional information.
For further details see:
Horizon Therapeutics shareholders overwhelmingly approve acquisition by Amgen